1,961 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Acquired by Brighton Jones LLC

Brighton Jones LLC bought a new stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) in the 3rd quarter, HoldingsChannel reports. The firm bought 1,961 shares of the biopharmaceutical company’s stock, valued at approximately $988,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. Ethic Inc. increased its holdings in shares of Madrigal Pharmaceuticals by 20.6% in the third quarter. Ethic Inc. now owns 598 shares of the biopharmaceutical company’s stock valued at $301,000 after buying an additional 102 shares in the last quarter. Parallel Advisors LLC lifted its position in shares of Madrigal Pharmaceuticals by 32.2% during the 3rd quarter. Parallel Advisors LLC now owns 349 shares of the biopharmaceutical company’s stock valued at $176,000 after acquiring an additional 85 shares during the last quarter. Allegiance Financial Group Advisory Services LLC bought a new stake in shares of Madrigal Pharmaceuticals during the 3rd quarter worth $219,000. Calamos Advisors LLC boosted its stake in shares of Madrigal Pharmaceuticals by 83.3% during the 3rd quarter. Calamos Advisors LLC now owns 3,009 shares of the biopharmaceutical company’s stock worth $1,516,000 after acquiring an additional 1,367 shares in the last quarter. Finally, Commonwealth Equity Services LLC boosted its stake in shares of Madrigal Pharmaceuticals by 2.7% during the 3rd quarter. Commonwealth Equity Services LLC now owns 1,664 shares of the biopharmaceutical company’s stock worth $839,000 after acquiring an additional 43 shares in the last quarter. 98.50% of the stock is owned by institutional investors and hedge funds.

Madrigal Pharmaceuticals Price Performance

NASDAQ MDGL opened at $433.03 on Thursday. The firm’s 50 day moving average price is $480.46 and its two-hundred day moving average price is $496.53. The company has a current ratio of 3.05, a quick ratio of 2.78 and a debt-to-equity ratio of 0.54. Madrigal Pharmaceuticals, Inc. has a twelve month low of $353.54 and a twelve month high of $615.00.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last released its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $1.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.09) by $2.92. The company had revenue of $431.27 million during the quarter, compared to analyst estimates of $404.17 million. Madrigal Pharmaceuticals had a negative return on equity of 27.08% and a negative net margin of 10.89%. During the same quarter in the prior year, the company earned ($5.08) earnings per share. As a group, sell-side analysts forecast that Madrigal Pharmaceuticals, Inc. will post -2.08 earnings per share for the current year.

Insider Activity

In related news, CEO William Sibold sold 6,362 shares of the stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $535.59, for a total value of $3,407,423.58. Following the completion of the sale, the chief executive officer directly owned 202,967 shares of the company’s stock, valued at approximately $108,707,095.53. This represents a 3.04% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Bros. Advisors Lp Baker acquired 76,140 shares of Madrigal Pharmaceuticals stock in a transaction that occurred on Friday, November 6th. The stock was acquired at an average cost of $384.32 per share, with a total value of $29,262,124.80. Following the completion of the purchase, the director owned 2,040,682 shares in the company, valued at approximately $784,274,906.24. This represents a 3.88% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have sold 13,324 shares of company stock worth $7,011,982. 17.60% of the stock is owned by corporate insiders.

Top Madrigal Pharmaceuticals Stories

Here are a few of the latest stories about MDGL:

• Positive Sentiment: A Zacks article included Madrigal among commercial-stage biotechs positioned for revenue growth, citing expanding product sales, rising demand, broader patient access and new market opportunities. Article: 4 Commercial-Stage Biotechs Poised for Sustained Revenue Growth
• Negative Sentiment: Hagens Berman said it is investigating whether Madrigal or senior management misrepresented or concealed material facts about Rezdiffra clinical safety data integrity and regulatory compliance. Kaplan Fox separately announced an investigation and invited investors who suffered losses to contact the firm. The allegations could raise concerns about legal, regulatory and reputational risk, although the notices do not establish wrongdoing and provide no details of a legal finding. Article: Hagens Berman Investigation Notice Article: Kaplan Fox Investigation Announcement

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. UBS Group restated a “buy” rating and issued a $735.00 target price on shares of Madrigal Pharmaceuticals in a report on Wednesday, October 14th. Truist Financial reaffirmed a “buy” rating and set a $743.00 target price (up from $709.00) on shares of Madrigal Pharmaceuticals in a report on Wednesday, November 4th. Barclays decreased their price target on Madrigal Pharmaceuticals from $964.00 to $962.00 and set an “overweight” rating for the company in a research report on Monday, August 3rd. Canaccord Genuity Group lifted their price target on Madrigal Pharmaceuticals from $612.00 to $633.00 and gave the stock a “buy” rating in a research note on Wednesday, November 4th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Madrigal Pharmaceuticals in a research note on Thursday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Madrigal Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $706.87.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. The company is headquartered in Conshohocken, Pennsylvania. Its lead product, Rezdiffra (resmetirom), is a thyroid hormone receptor-beta agonist. The U.S. Food and Drug Administration approved Rezdiffra in 2024 for use with diet and exercise in adults with noncirrhotic MASH and moderate-to-advanced liver fibrosis.